The platforms that turn biological potential into practical medicines and devices.
A discovery becomes a medicine through thousands of repeatable decisions. Step inside the less visible world that turns a promising result into reliable supply.
4 min read
Vyxeos provides the clinical anchor; a separate yield and cash-cost model tests whether a manufacturing improvement deserves investment.
SYMPLICITY HTN-3 frames a hypothetical device trial budget, site plan and milestone gate.
Genzyme’s remediation history anchors a hypothetical outage-exposure and backup-capacity decision.
A historical gene-therapy data issue informs a hypothetical audit, remediation and transaction-delay model.
Kymriah and current cell-therapy commercialization frame manufacturing reliability, release timing and patient readiness.
![Original Casgevy study: retain the denominators. Treated: 44; Efficacy evaluable: 31; Met VF12 endpoint: 29. Patients. 2023 FDA review [1]; nested groups, not independent cohorts.](/images/consulting/casgevy-treatment-center-capacity-economics-record.svg)
Original gene-editing evidence and 2026 launch revenue inform a hypothetical treatment-center capacity model.
Living cells and carefully engineered channels offer a new window into human biology. The important question is which part of an organ a tiny model can faithfully represent.
4 min read
Coordinate clinical, regulatory and manufacturing decisions with clear ownership, acceptance criteria and measurable handoffs.
A small Phase I study provides a useful early signal and a clear boundary around what remains to be demonstrated.
A randomized breast-cancer trial shows why efficacy and adverse-event context belong in the same product discussion.
Two randomized trials illustrate how to communicate a strong biomarker result without extending it beyond the measured outcome.
The NIH titration-screening example shows why a richer experiment can matter more than a throughput ranking.
A historical storage change shows why a process convenience needs product-specific supporting data.
The 2018 contraceptive-ring program separates duration, pregnancy outcomes, and real-world handling.
The original 2014 authorization illustrates how a delivery route adds screening and monitoring dependencies.